Evidence map›Paper›PMID 40024743›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2025

Prognostic predictors of newly diagnosed Diffuse large B-cell lymphoma treated with R-THP-COP regimen.

Yoshiaki Okano, Tatsuo Oyake, Sawako Kitamura, Kazuya Asano, Tsuyoshi Sato, Takahiro Maeta, Shinri Miyajima, Akihiro Otsu, Maki Nishiya, Ryousei Sasaki and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yoshiaki OkanoDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Tatsuo OyakeDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Sawako KitamuraDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Kazuya AsanoDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Tsuyoshi SatoDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Takahiro MaetaDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Shinri MiyajimaDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Akihiro OtsuDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Maki NishiyaDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Ryousei SasakiDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Shugo KowataDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Yoji IshidaDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Shigeki ItoDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognostic value of models such as the international prognostic index (IPI) in patients with malignant lymphomas treated with a combination of rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisolone is well established. However, whether these prognostic models apply to patients treated with a combination of tetrahydropyranyl adriamycin, rituximab, cyclophosphamide, vincristine, and prednisolone (R-THP-COP) is unclear. This retrospective analysis included 101 patients with Diffuse large B-cell lymphoma (DLBCL) treated with R-THP-COP. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), complete response rate (CRR), and effectiveness of risk prediction in the IPI, revised international prognostic index (R-IPI), and National Comprehensive Cancer Network (NCCN)-IPI groups. OS and PFS at 5 years were 67% and 58.9%. CRR was 63.5%. The IPI, R-IPI, and NCCN-IPI predicted the outcomes of patients treated with R-THP-COP. According to the NCCN-IPI, OS and PFS could distinguish four risk groups. In conclusion, the NCCN-IPI is the most effective prognostic tool for identifying patients with poor prognosis, even those treated with R-THP-COP.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overCyclophosphamideDoxorubicinFemaleHumansMaleMiddle AgedPrednisolonePrognosisRetrospective StudiesRituximabVincristineCyclophosphamideDoxorubicinPrednisoloneRituximabVincristineDiffuse large B-cell lymphomainternational prognostic indexNational Comprehensive Cancer Network-IPIpirarubicinrevised international prognostic index

Identifiers

PMID40024743
PMCPMC12051418

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.